The International Vaccine Institute (IVI) and Bharat Biotech have started a Phase 2/3 clinical trial for a chikungunya vaccine candidate in Costa Rica.
Novartis’s Kymriah CAR-T therapy did not meet its primary endpoint of event-free survival in a phase 3 study in patients with aggressive B-cell non-Hodgkin lymphoma (NHL) after relapse or lack of response to first-line treatment.
AZD7442, a combination of two long-acting antibodies (LAAB), reduced the risk of developing symptomatic COVID-19 by 77%, according to results from a Phase 3 trial.
There is “sizable demand” from manufacturers of COVID-19 vaccines for vials out to 2023, suggesting that the market will remain significant for some time.
CureVac and GSK said their jointly advanced second-generation mRNA COVID-19 vaccine candidate, CV2CoV, demonstrated improved immune response and protection in a preclinical study.
Vaccine company Valneva has announced positive Phase 3 pivotal results for its single-shot chikungunya vaccine. “We are a step closer to addressing this major, growing and unmet public health threat,” says the company.
The non-digestible polysaccharide Arabinoxylan may be an effective oral adjuvant to support vaccine efficacy, according to a new pilot study involving 231 elderly participants.
Arcturus Therapeutics and its Vietnam partner Vinbiocare will take ARCT-154, a next-generation Arcturus vaccine targeting SARS-CoV-2 variants of concern, into a Phase 1/2/3 trial. The companies will also establish a vaccine manufacturing centre in Vietnam....
